CEO Murat Cirit describes how the liver tissue chip and accompanying software is meant to improve the quality of preclinical research.

Jing Wang explains how her company is focused on restoring CNS conditions such as MS and ALS, and talks targets.

McKinsey Boston life science specialists give their take on the goals of the summit and the current state of the sector.

Chris Bahl walks through the attributes of miniproteins.

He talks about GV's history in healthcare and lists some investments made in the nearly five years he has been there.

Kendalle Burlin O'Connell describes the goals of the Align Summit and the work MassBio is doing.

Francisco LePort and Martin Borch Jensen describe the science behind the mosiac screening process.

Ronald Martell describes Jasper's subcu programs for urticaria.

He discusses Intra-Cellular, Axsome, Adaptimmune, EyePoint, Insmed, Immunocore, Immatics, and Terns.

CEO Adrian Rawcliffe describes how Adaptimmune is preparing to launch what could be the first approved TCR based cell therapy in the U.S.

Eddie Eltoukhy explains the unique role that seed investors have in helping entrepreneurs succeed, he lists some areas of science of...

Chaitan Khosla, Director of the Innovative Medicines Accelerator, describes how Stanford goes extra lengths to turn its research into...

Emil Kakkis summarizes Ultragenyx's Angelman syndrome update at AAN and more.

He discusses Vertex's acquisition of Alpine Immune Science, Bloomberg's reporting on Janux, and more.

Bill Sibold describes how Madrigal has prepared for the launch and illustrates how the medicine is meant to impact disease progression.

Darrin Miles describes how this molecular glue therapy has been designed to bind to MEK and all isoforms of MEK and RAF in combination.

EpicentRx CEO Tony Reid and MD Andersen investigator Anthony Conley describe TGF-β data presented at AACR.

She describes working with Steven Paul again, the Glyph technology that is the backbone of Seaport's platform, and more.

Dr. Yu describes how TCGX's structure and nimbleness has led to investments in number companies that have been acquired over the last year.

CEO Eamonn Hobbs describes the responses Syncromune is seeing in an early phase 1 prostate cancer study.